PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.
North America is the largest consumption place, with a consumption market share nearly 60.40% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 20.66%.Market competition is intense. Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical etc. are the leaders of the industry.

In 2020, the global PD-1 and PD-L1 Inhibitors market size was US$ 39550 million and is forecast to 119290 million US in 2027, growing at a CAGR of 20.2% during the 2021-2027. In this study, 2020 has been considered as the base year and 2021 to 2027 as the forecast period to estimate the market size for PD-1 and PD-L1 Inhibitors.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global PD-1 and PD-L1 Inhibitors market. The analysts authoring the report have closely studied key strategies adopted by top players of the global PD-1 and PD-L1 Inhibitors market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global PD-1 and PD-L1 Inhibitors market. Readers of the report can become informed about current and future trends of the global PD-1 and PD-L1 Inhibitors market and how they will impact market growth during the forecast period.

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors

Segment by Application
Solid Tumors
Blood-related Tumors

By Company
Merck
Bristol-Myers Squibb
Roche
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Merck KGaA